The short version of Peptide stability fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-09. Anything still debated is marked as such rather than presented as settled.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Friedrich Engelhorn Heinrich von Brunck Carl Bosch Carl Wurster Bernhard Timm Matthias Seefelder Jürgen Strube 1990-2003 Jürgen Hambrecht 2003-2011 Kurt Bock 2011-2018 Martin Brudermüller 2018-2024 Markus Kamieth 2024–present
=== Phrixotoxin-1 === Mice that are injected with phrixotoxin-1 can experience numerous, transient, adverse cardiac reactions, such as premature ventricular beats, ventricular tachycardia, and atrio-ventricular blocks. Neurological effects observed are motor impairment and convulsions. These effects are seen following both intravenous and intracisternal injection, making it likely that phrixotoxin-1 crosses the blood brain barrier (Diochot 1999).
Following the accession of Franz Joseph to the throne in 1848, the political representatives of the Kingdom of Bohemia hoped and insisted that account should be taken of their historical state rights in the upcoming constitution. They felt the position of Bohemia within the Habsburg monarchy should have been highlighted by a coronation of the new ruler to the king of Bohemia in Prague (the last coronation took place in 1836). However, before the 19th century the Habsburgs had ruled Bohemia by hereditary right and a separate coronation was not deemed necessary. His new government installed the system of neoabsolutism in Austrian internal affairs to make the Austrian Empire a unitary, centralised and bureaucratically administered state. When Franz Joseph returned to constitutional rule after the debacles in Italy at Magenta and Solferino and summoned the diets of his lands, the question of his coronation as king of Bohemia again returned to the agenda, as it had not since 1848. On 14 April 1861, Emperor Franz Joseph received a delegation from the Bohemian Diet with his words (in Czech):
Sources: en.wikipedia.org
Major League Baseball's drug policy prohibits players from using, possessing, selling, facilitating the sale of, distributing, or facilitating the distribution of any Drug of Abuse and/or Steroid. Any and all drugs or substances listed under Schedule II of the Controlled Substances Act are considered drugs of abuse covered by the Program. Players who require prescription medication can still use it with a "Therapeutic Use Exemption" granted by MLB. In December 2019, MLB removed cannabinoids and added cocaine and opiates to its list of Drugs of Abuse. However, players were told that they could still be suspended for possessing or selling cannabis, or driving under the influence of cannabis.
==== New drug smuggling conviction and deportation to Belgium ==== On the evening of 19 July 2008, Olofsson and three other people were arrested next to Apelviken's campsite in Varberg. The police had him under surveillance for eight months and he was suspected of being the head in a large drug operation. At the same time, the police cracked down on a drug transport at Årsta partihallar in Stockholm. A total of six people were arrested in Stockholm and Varberg on suspicion of serious drug offenses. Olofsson was charged at the end of 2008 for trying to smuggle in 100 kilos of amphetamine and 76 kilos of cannabis from the Netherlands. The police of Östergötland had tracked down the drug smugglers through reconnaissance films and wiretapping since 2007. The trial began on 2 June 2009 and he was sentenced on 31 July 2009 to 14 years in prison, followed by life-time deportation, by the Linköping District Court for an aggravated drug offense and attempted aggravated drug offense. He was sentenced to nine years in prison for his drug dealing and was forced to serve another five years for continuing his crime following a previous conviction. When he returned to crime after his release in 2005, the district court had confiscated five years of his conditional release of seven years and thus Olofsson's sentence was in practice 14 years. On 7 December 2009, the prison sentence was upheld by Göta Court of Appeal. Until the autumn of 2012, Olofsson was incarcerated at Saltvik Prison in Härnösand before he was moved to Kumla Prison.
== Biosynthesis == Gramicidin S biosynthetic pathway consists of two-enzyme of nonribosomal peptide synthases (NRPSs), gramicidin S synthetase I (GrsA) and gramicidin S synthetase II (GrsB), to give a product as a cyclic decapeptide. Within the biosynthetic pathway, there are total of five modules that specifically recognize, activate, and condense the amino acids to gramicidin S. Starting module GrsA consists of three domains: Adenylation (A) domain where it incorporates the amino acid and activates it by adenylation using ATP, Thiolation (T) domain or peptidyl carrier protein (PCP) in which the adenylated amino acid gets covalently attached to the 4´-phosphopantetheine group and this gets loaded onto the conserved serine in the T domain, Epimerization (E) domain where it epimerizes L-amino acid to D-amino acid. Starting module GrsA loads D-Phe onto the system. Second enzyme cluster GrsB contains four modules, each containing condensation (C), adenylation (A), and thiolation (T) domains and thioesterase domain (TE) at the end. C domain forms a peptide bond between two amino acids, D-Phe and L-Pro. L-Val, L-Orn, and L-Leu are incorporated sequentially by the next three modules of GrsB. After repeating the whole module synthesis once again, TE domain cyclizes and releases the two peptides and dimerize them together to form the final product.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.